Evaluating the Effectiveness of Intranasal Butorphanol in Reducing Chronic Itch

Authors

  • Angelina Labib UM Department of Dermatology
  • Teresa Ju
  • Zoe Morgan Lipman
  • Gil Yosipovitch Dr Phillip Frost Department of Dermatology and Cutaneous Surgery and Miami Itch Center, University of Miami Miller School of Medicine, 1600 NW 10th Ave RMSB Building 2067B, Miami, FL, USA

DOI:

https://doi.org/10.2340/actadv.v102.2153

Keywords:

chronic itch, pruritus, butorphanol

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Yosipovitch G, Greaves MW, McGlone F. Itch: basic mechanisms and therapy. Boca Raton, CRC Press; 2004.

https://doi.org/10.1201/b14233

Umehara Y, Kiatsurayanon C, Trujillo-Paez JV, Chieosilapatham P, Peng G, Yue H, et al. Intractable itch in atopic dermatitis: causes and treatments. Biomedicines 2021; 9: 229.

https://doi.org/10.3390/biomedicines9030229

Zeidler C, Yosipovitch G, Ständer S. Prurigo nodularis and its management. Dermatol Clin 2018; 36: 189-197.

https://doi.org/10.1016/j.det.2018.02.003

Zachariae R, Lei U, Haedersdal M, Zachariae C. Itch severity and quality of life in patients with pruritus: preliminary validity of a Danish adaptation of the itch severity scale. Acta Derm Venereol 2012; 92: 508-514.

https://doi.org/10.2340/00015555-1221

Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol 2006; 54: 527-531.

https://doi.org/10.1016/j.jaad.2005.12.010

Khanna R, Kwon CD, Patel SP, Belzberg M, Williams KA, Khanna R, et al. Intranasal butorphanol rescue therapy for the treatment of intractable pruritus: a case series from the Johns Hopkins Itch Clinic. J Am Acad Dermatol 2020; 83: 1529-1533.

https://doi.org/10.1016/j.jaad.2020.07.017

Yosipovitch G, Reaney M, Mastey V, Eckert L, Abbé A, Nelson L, et al. Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol 2019; 181: 761-769.

https://doi.org/10.1111/bjd.17744

Beck TC, Hapstack MA, Beck KR, Dix TA. Therapeutic potential of kappa opioid agonists. Pharmaceuticals (Basel) 2019; 12: 95.

https://doi.org/10.3390/ph12020095

Reszke R, Krajewski P, Szepietowski JC. Emerging therapeutic options for chronic pruritus. Am J Clin Dermatol 2020; 21: 601-618.

https://doi.org/10.1007/s40257-020-00534-y

Mathur VS, Kumar J, Crawford PW, Hait H, Sciascia T. A multicenter, randomized, double-blind, placebo-controlled trial of nalbuphine ER tablets for uremic pruritus. Am J Nephrol 2017; 46: 450-458.

https://doi.org/10.1159/000484573

Hawi A, Alcorn H, Jr, Berg J, Hines C, Hait H, Sciascia T. Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus. BMC Nephrol 2015; 16: 47.

https://doi.org/10.1186/s12882-015-0043-3

Weisshaar E, Szepietowski JC, Bernhard JD, Hait H, Legat FJ, Nattkemper L, et al. Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open-label extension phase. J Eur Acad Dermatol Venereol 2022; 36: 453-461.

https://doi.org/10.1111/jdv.17816

Kremer AE. What are new treatment concepts in systemic itch? Exp Dermatol 2019; 28: 1485-1492.

https://doi.org/10.1111/exd.14024

Deeks ED. Difelikefalin: first approval. Drugs 2021; 81: 1937-1944.

https://doi.org/10.1007/s40265-021-01619-6

Kumagai H, Ebata T, Takamori K, Miyasato K, Muramatsu T, Nakamoto H, et al. Efficacy and safety of a novel ĸ-agonist for managing intractable pruritus in dialysis patients. Am J Nephrol 2012; 36: 175-183.

https://doi.org/10.1159/000341268

Downloads

Published

2022-06-09

How to Cite

Labib, A., Ju, T., Lipman, Z. M., & Yosipovitch, G. (2022). Evaluating the Effectiveness of Intranasal Butorphanol in Reducing Chronic Itch. Acta Dermato-Venereologica, 102, adv00729. https://doi.org/10.2340/actadv.v102.2153

Issue

Section

Short Communication

Categories